Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
about
A review of 2014 cancer drug approvals, with a look at 2015 and beyond.Fibroblast growth factors, old kids on the new block.Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerLenvatinib: first global approval.Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.Lenvatinib: A Review in Refractory Thyroid Cancer.Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.Crystal structure, Hirshfeld analysis and mol-ecular docking with the vascular endothelial growth factor receptor-2 of (3Z)-5-fluoro-3-(hy-droxy-imino)-indolin-2-one.Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report.Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.Atropisomerism in medicinal chemistry: challenges and opportunities.Discovery of wt RET and V804M RET Inhibitors: From Hit to Lead.Structure and function of vascular endothelial growth factor and its receptor system.Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
P2860
Q35170573-42B20A9B-972E-4DB7-8F31-44B9DFB23B22Q36923642-77E9FCBD-AB91-4175-8119-4F8D3C0B67B1Q37393234-40F20466-E2C0-485E-A954-63014CB5C8CBQ38385844-093FCF48-172F-45D7-9920-7B45C862F28AQ38701634-0AE2831C-8C76-4791-A7C5-4EF0283F967AQ38729953-D882B51B-ABED-4AE1-8133-0F27B5120DB4Q38754614-EA206F4C-08EE-4E61-A4E1-64A33D2177CFQ40953285-A63FAE0A-CB65-4133-B84A-076EE673D6F4Q41954414-16BBD5EA-6C89-4EBC-B0B8-E0F85885835BQ46173337-7C34CCF9-A3B9-409F-B344-CBCC5FCF6930Q47705234-5AABCA1E-0033-4CB3-AE57-C2E2D23C3844Q48238438-4BC615CB-75D4-4112-A8E1-BFF987E1D3B3Q49346926-103B1FE4-C7A8-4A88-BCE4-F5210840E869Q54111915-582B9EB0-FE2D-4ED3-957A-DB8B5A414611Q57809492-28348EF6-0D48-43DF-8729-D279B9D77EDF
P2860
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Distinct binding mode of multi ...... biochemical characterization.
@en
type
label
Distinct binding mode of multi ...... biochemical characterization.
@en
prefLabel
Distinct binding mode of multi ...... biochemical characterization.
@en
P2093
P2860
P356
P1476
Distinct binding mode of multi ...... biochemical characterization.
@en
P2093
Akihiko Tsuruoka
Anja Jestel
Atsushi Inoue
Junji Matsui
Kiyoshi Okamoto
Konstanze von König
Megumi Ikemori-Kawada
Tomohiro Matsushima
Yasuhiro Funahashi
P2860
P356
10.1021/ML500394M
P577
2014-11-17T00:00:00Z